Patents by Inventor Timo Jämsä

Timo Jämsä has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11804290
    Abstract: Highblood levels of very low density lipoprotein lipids (VLDLs) and glycoprotein acyl (Glyc A) are known to increase risk of diabetes, cardiovascular diseases, inflammations, cognitive impairments, cancers and premature deaths in sedentary persons. The invention determines physical activity thresholds of daily steps and accelerations to reduce plasma concentrations of VLDLs and Glyc A. The method and device is an accelerometer recording and classifying numbers of steps and accelerations and comparing the person's steps and accelerations with those shown to reduce VLDLs and Gly A. The invention is characterized in that if the daily number of accleration maxima exceeds the given en threshold of 2980 steps in the acceleration range 1.3-1.7 g, the person has performed physical activity, typically known to reduce circulating VLDLs and Glyc A.
    Type: Grant
    Filed: August 29, 2018
    Date of Patent: October 31, 2023
    Assignee: Gleap Health Technologies Oy
    Inventors: Juhani Leppäluoto, Sirkka Keinänen-Kiukaanniemi, Timo Jämsä, Jari Jokelainen, Karl-Heinz Herzig
  • Publication number: 20200202995
    Abstract: Highblood levels of very low density lipoprotein lipids (VLDLs) and glycoprotein acyl (Glyc A) are known to increase risk of diabetes, cardiovascular diseases, inflammations, cognitive impairments, cancers and premature deaths in sedentary persons. The invention determines physical activity thresholds of daily steps and accelerations to reduce plasma concentrations of VLDLs and Glyc A. The method and device is an accelerometer recording and classifying numbers of steps and accelerations and comparing the person's steps and accelerations with those shown to reduce VLDLs and Gly A. The invention is characterized in that if the daily number of accleration maxima exceeds the given en threshold of 2980 steps in the acceleration range 1.3-1.7 g, the person has performed physical activity, typically known to reduce circulating VLDLs and Glyc A.
    Type: Application
    Filed: August 29, 2018
    Publication date: June 25, 2020
    Applicant: Gleap Health Technologies Oy
    Inventors: Juhani LEPPÄLUOTO, Sirkka KEINÄNEN-KIUKAANNIEMI, Timo JÄMSÄ, Jari JOKELAINEN, Karl-Heinz HERZIG
  • Publication number: 20190290191
    Abstract: Discloses are method and device determining threshold values for the volume and intensity of physical activity and the lowest levels of this activity that reduce risk factors in overweight persons who suffer from disorders of sugar and lipid metabolism. The method comprises of registering a person's daily physical activity, comparing it with the measured/predetermined threshold levels and informs the person, if the volume and/or intensity of the physical activity has been sufficient to prevent the effects of disease risk factors. Based on the disclosed methodology, overweight persons having disorders in sugar and lipid metabolism are able to perform physical activity maintaining health and reducing the risk factors. The invention described herein demonstrates a novel opportunity for overweight people having an abnormal blood sugar to use the low intensity physical activity to restrain risk factors related to cardiovascular diseases, diabetes and obesity.
    Type: Application
    Filed: June 12, 2019
    Publication date: September 26, 2019
    Applicant: Gleap Health Technologies Oy
    Inventors: Juhani LEPPÄLUOTO, Karl-Heinz HERZIG, Riikka AHOLA, Timo JÄMSÄ, Jari JOKELAINEN, Sirkka KEINÄNEN-KIUKAANNIEMI
  • Publication number: 20100137107
    Abstract: A measuring device and a method estimates the quantity and quality of exercises performed having an advantageous impact on cholesterol metabolism. In the method, accelerations exerted on a person during daily exercise performed by the person are continuously recorded by a measuring device including an acceleration transducer. The recorded results are visible in the measuring device or an external device. Based on the received feedback, the person can change the quantity and quality of his/her exercise so that it has an advantageous impact on cholesterol metabolism.
    Type: Application
    Filed: December 10, 2007
    Publication date: June 3, 2010
    Applicant: NEWTEST OY
    Inventors: Timo Jämsä, Juhani Leppäluoto, Ari Jämsen, Anneli Rinta-Paavola, Erkki Vihriälä